Pathophysiology of diabetes mellitus type 2: Roles of obesity, insulin resistance and β-cell dysfunction

Frontiers in Diabetes

Volumn 19, Issue , 2008, Pages 1-18

  Thévenod, Frank ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 52949128784     PISSN: 02515342     EISSN: 16622995     Source Type: Book Series    
DOI: 10.1159/000152019     Document Type: Article

References (71)

1. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001; 414:782-787.
2. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB: Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343.
3. Hotamisligil GS: The role of TNF-ot and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-625.
4. Rotter V, Nagaev I, Smith U: Interleukin (IL)-6 induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-a, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003;278:45777-45784.
5. Rosen ED, Spiegelman BM: Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006;444:847-853.
6. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-362.
7. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-2563.
8. Newsholme P, Keane D, Welters HJ, Morgan NG: Life and death decisions of the pancreatic β-cell: the role of fatty acids. Clin Sci (Lond) 2007;112:27-42.
9. Eldor R, Raz I: Lipotoxicity versus adipotoxicity -the deleterious effects of adipose tissue on β cells in the pathogenesis of type 2 diabetes. Diabetes Res Clin Pract 2006;74:S3-S8.
10. Lowell BB, Shulman GI: Mitochondrial dysfunction and type 2 diabetes. Science 2005;307:384-387.
11. Saleh MC, Wheeler MB, Chan CB: Uncoupling protein-2: evidence for its function as a metabolic regulator. Diabetologia 2002;45:174-187.
12. Saltiel AR, Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414:799-806.
13. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene 2003;22:8983-8998.
14. Flier JS: Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116:337-350.
15. Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat Med 2004; 10: 355-361.
16. Ruan H, Lodish HF: Regulation of insulin sensitivity by adipose tissue-derived hormones and inflammatory cytokines. Curr Opin Lipidol 2004;15:297-302.
17. Duncan RE, Ahmadian M, Jaworski K, Sarkadi-Nagy E, Sul HS: Regulation of lipolysis in adipocytes. Annu Rev Nutr 2007;27:79-101.
18. Montani JP, Antic V, Yang Z, Dulloo A: Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes Relat Metab Disord 2002;26(suppl 2):S28-S38.
19. Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801.
20. Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-783.
21. Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM, Ranganathan G, Peterson CA, McGehee RE, Kern PA: Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005;54:2305-2313.
22. Boden G, Laakso M: Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care 2004;27:2253-2259.
23. Kim JK, Gimeno RE, Higashimori T, Kim HJ, Choi H, Punreddy S, Mozell RL, Tan G, Stricker-Krongrad A, Hirsch DJ, Fillmore JJ, Liu ZX, Dong J, Cline G, Stahl A, Lodish HF, Shulman GI: Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle. J Clin Invest 2004;113:756-763.
24. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA, Hotamisligil GS: Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005;1:107-119.
25. Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL: Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999;48:1836-1841.
26. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-189.
27. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000;106:171-176.
28. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, Tanaka H, Maruyama M, Satoh R, Okubo S, Kizawa H, Komatsu H, Matsumura F, Noguchi Y, Shinohara T, Hinuma S, Fujisawa Y, Fujino M: Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature 2003;422:173-176.
29. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H: The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 2005;1: 245-258.
30. Kahn SE, Hull RL, Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-846.
31. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, et al: Quantification of the relationship between insulin sensitivity and β -cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42:1663-1672.
32. MacDonald PE, Joseph JW, Rorsman P: Glucosesensing mechanisms in pancreatic β-cells. Philos Trans R Soc Lond B Biol Sci 2005;360:2211-2225.
33. Chen C, Hosokawa H, Bumbalo LM, Leahy JL: Mechanism of compensatory hyperinsulinemia in normoglycemic insulin-resistant spontaneously hypertensive rats. Augmented enzymatic activity of glucokinase in β-cells. J Clin Invest 1994;94:399-404.
34. Liu YQ, Jetton TL, Leahy JL: β;-Cell adaptation to insulin resistance. Increased pyruvate carboxylase and malate-pyruvate shuttle activity in islets of non-diabetic Zucker fatty rats. J Biol Chem 2002;277: 39163-39168.
35. Drucker DJ: The biology of incretin hormones. Cell Metab 2006;3:153-165.
36. Hull RL, Kodama K, Utzschneider KM, Carr DB, Prigeon RL, Kahn SE: Dietary-fat-induced obesity in mice results in β-cell hyperplasia but not increased insulin release: evidence for specificity of impaired β-cell adaptation. Diabetologia 2005;48: 1350-1358.
37. Prentki M, Nolan CJ: Islet β cell failure in type 2 diabetes. J Clin Invest 2006;116:1802-1812.
38. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU: Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985;4:110-125.
39. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110.
40. Rhodes CJ: Type 2 diabetes - a matter of β-cell life and death? Science 2005;307:380-384.
41. Kahn SE: The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19.
42. Van Haeften TW, Dubbeldam S, Zonderland ML, Erkelens DW: Insulin secretion in normal glucose-tolerant relatives of type 2 diabetic subjects. Assessments using hyperglycemic glucose clamps and oral glucose tolerance tests. Diabetes Care 1998;21: 278-282.
43. UK Prospective Diabetes Study Group (UKPDS): UK Prospective Diabetes Study 16: overview of 6 years' therapy of type 2 diabetes: a progressive disease. Diabetes 1995;44:1249-1258.
44. Gerich JE: The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998;19:491-503.
45. Taylor SI: Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992;41: 1473-1490.
46. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr: Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984;74:1318-1328.
47. Fritsche A, Stefan N, Hardt E, Haring H, Stumvoll M: Characterisation of β-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretininduced insulin secretion. Diabetologia 2000;43: 852-858.
48. Kjems LL, Hoist JJ, Volund A, Madsbad S: The influence of GLP-I on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003;52:380-386.
49. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type 2 diabetes mellitus. Diabetes 1985;34:222-234.
50. Kahn SE, Bergman RN, Schwartz MW, Taborsky GJ Jr, Porte D Jr: Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans. Am J Physiol 1992; 262:E518-E523.
51. Barroso I: Genetics of type 2 diabetes. Diabet Med 2005;22:517-535.
52. Schwanstecher C, Meyer U, Schwanstecher M: K(IR)6.2 polymorphism predisposes to type 2 diabetes by inducing overactivity of pancreatic β-cell ATP-sensitive K+ channels. Diabetes 2002;51: 875-879.
53. 't Hart LM, van Haeften TW, Dekker JM, Bot M, Heine RJ, Maassen JA: Variations in insulin secretion in carriers of the E23K variant in the KIR6.2 subunit of the ATP-sensitive K+ channel in the β-cell. Diabetes 2002;51:3135-3138.
54. Ellard S, Flanagan SE, Girard CA, Patch AM, Harries LW, Parrish A, Edghill EL, Mackay DJ, Proks P, Shimomura K, Haberland H, Carson DJ, Shield JP, Hattersley AT, Ashcroft FM: Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am J Hum Genet 2007; 81:375-382.
55. Gloyn AL: Glucokinase (GCK) mutations in hyperand hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum Mutat 2003;22:353-362.
56. Maechler P, de Andrade PB: Mitochondrial damages and the regulation of insulin secretion. Biochem Soc Trans 2006;34:824-827.
57. Krempler F, Esterbauer H, Weitgasser R, Ebenbichler C, Patsch JR, Miller K, Xie M, Linnemayr V, Oberkofler H, Patsch W: A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans. Diabetes 2002;51:3331-3335.
58. Esterbauer H, Schneitier C, Oberkofler H, Ebenbichler C, Paulweber B, Sandhofer F, Ladurner G, Hell E, Strosberg AD, Patsch JR, Krempler F, Patsch W: A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001;28:178-183.
59. Sesti G, Cardellini M, Marini MA, Frontoni S, D'Adamo M, Del Guerra S, Lauro D, De Nicolais P, Sbraccia P, Del Prato S, Gambardella S, Federici M, Marchetti P, Lauro R: A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. Diabetes 2003;52:1280-1283.
60. Poulton J, Luan J, Macaulay V, Hennings S, Mitchell J, Wareham NJ: Type 2 diabetes is associated with a common mitochondrial variant: evidence from a population-based case-control study. Hum Mol Genet 2002;11:1581-1583.
61. Hales CN, Barker DJ: Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992;35:595-601.
62. Michikawa Y, Mazzucchelli F, Bresolin N, Scarlato G, Attardi G: Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science 1999;286:774-779.
63. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD: Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988;37:1020-1024.
64. Gribble FM, Proks P, Corkey BE, Ashcroft FM: Mechanism of cloned ATP-sensitive potassium channel activation by oleoyl-CoA. J Biol Chem 1998;273: 26383-26387.
65. Zhou YP, Grill VE: Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 1994;93:870-876.
66. Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF: Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol 1999;276: E1055-E1066.
67. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR: Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000;6:87-97.
68. Miyake K, Ogawa W, Matsumoto M, Nakamura T, Sakaue H, Kasuga M: Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver. J Clin Invest 2002;110:1483-1491.
69. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bemal D, Pons S, Shulman GI, Bonner-Weir S, White MF: Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998;391: 900-904.
70. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR: Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999;96:329-339.
71. Pospisilik JA, Knauf C, Joza N, Benit P, Orthofer M, Cani PD, Ebersberger I, Nakashima T, Sarao R, NeeIy G, Esterbauer H, Kozlov A, Kahn CR, Kroemer G, Rustin P, Burcelin R, Penninger JM: Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell 2007;131:476-491.